Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19

Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited.

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sabestomig?

Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Non-Small Cell Lung Carcinoma.

April 17, 2024

SCA4 genetic breakthrough: Unveiling the cause of a devastating neurological disease

Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is

April 29, 2024

Income inequality linked to 10-year gap in life expectancy, study reveals

During the past 40 years, the gap between rich and poor Americans has continued to widen in terms of health and mortality, as well as

May 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.